الخميس 10 محرم 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| A 24-week, multicentre, non-interventional, prospective study to describe clinical outcomes of advancing therapy with iGlarLixi in patients with T2DM sub-optimally controlled on basal insulin with or without OADs in daily practice in Saudi Arabia | Sanofi | Ongoing | iGlarLixi | 4 | OBS17984 | King Fahad Medical City (Riyadh) |
| REFINE-IO An Observational study in patients with unresectable hepatocellular carcinoma (uHCC) following treatment with atezolizumab plus bevacizumab (AB) or with another approved immunooncology immune checkpoint inhibitor combination in first-line. | Bayer Saudi Arabia LLC | Ongoing | ATC L01XE21, Protein kinase inhibitors, Regorafenib, Sorafenib, | 4 | 22453 | King Faisal Specialist Hospital and Research Center (Jeddah) |
| Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi- Center, Open-Label, Single-Arm, Phase II, PET-Adaptive Study | King Abdullah International Medical Research Center (KAIMRC) | Rejected | BRENTUXIMAB VEDOTIN , DOXORUBICIN HYDROCHLORIDE , VINBLASTINE SULPHATE , Dacarbazine | 2 | RJ19/119/J | King Abdulaziz Medical City NG (Jeddah) |
| A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl-β-cyclodextrin) and Standard of Care Compared to Placebo and Standard of Care in Patients with Niemann-Pick Disease Type C1 | Cyclo Therapeutics, Inc | Ongoing | Hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) | 3 | CTD-TCNPC-301 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients with Congenital Hyperinsulinism | Rezolute Inc | Ongoing | RZ358 | 3 | RZ358-301 | King Abdulaziz Medical City NG (Riyadh) |
| Modified Quadruple Therapy Regimen for Helicobacter pylori Eradication – A Prospective Randomized Controlled Trial | King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia | Ongoing | Bismuth Subcitrate Potassium , Tetracycline , Metronidazol | 2 | 2231295 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER | Roche | Ongoing | Giredestrant , Phesgo | 3 | WO43571 | King Abdulaziz Medical City NG (Riyadh) , King Fahad Medical City (Riyadh) |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension | Astrazeneca | Ongoing | Baxdrostat | 3 | D6970C00009 | King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh) |
| The effect of novel D3 use as a mouthwash in COVID-19 patients | King Faisal Specialist Hospital & Research Centre Jeddah, Saudi Arabia | Ongoing | Cholecalciferol (vitamin D) | 3 | 2022-32 | King Faisal Specialist Hospital and Research Center (Jeddah) |
| A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya®(somapacitan) in adults with growth hormone deficiency (AGHD) under routine clinical practice | NovoNordisk | Ongoing | Sogroya® | 4 | NN8640-451 | My Clinic (Jeddah),King Fahad Medical City (Riyadh),Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh) |
تاريخ آخر تحديث: 08/05/2025 بتمام الساعة 03:17 مساء بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.